Skip to main content
. 2020 Jan 3;11(2):426–435. doi: 10.1111/1759-7714.13289

Table 4.

Univariate analysis of overall survival (OS) from the initiation of AMR therapy

Overall survival (OS)
Variables Hazard ratio 95% CI P‐value
Age (≤ 66 vs. ≥ 67 years) 1.58 0.87–3.08 0.13
Gender (male vs. female) 1.24 0.64–2.37 0.53
PS (0 vs.1,2) 0.37 0.15–0.58 <0.01
Stage (IIIA, IIIB vs. IV) 0.22 0.15–0.57 <0.01
EGFR mutation status (mutation vs. wild‐type, unknown) 0.99 0.46–2.13 0.97
Histology (adenocarcinoma vs. nonadenocarcinoma) 1.10 0.56–2.13 0.79
Smoking status (smoker vs. non‐smoker) 1.25 0.66–2.36 0.51
Number of regimens before AMR (<3 vs. ≥ 3) 0.59 0.31–1.08 0.09
Response to AMR (PR vs. SD, PD) 0.43 0.23–1.25 0.15
topoisomerase‐II (low vs. high) 0.47 0.16–0.84 0.02
Ki‐67 labeling index (<20 LI vs. ≥20 LI) 1.09 0.59–2.02 0.79

AMR, amrubicin; CI, confidence interval; CR, complete response; EGFR, epidermal growth factor receptor; HR, hazard ratio; LI, labeling index; OS, overall survival; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease.